BDNF and Alzheimer disease: However, to account for the possible effect of AD and MS medications on BDNF and trkB−TK+ mRNA levels, ANOVAs were performed on all areas comparing subjects on ADs at the time of death (n=24), patients free of ADs at time of death (n=21), and unaffected controls (n=15).